gene_symbol
FCGR2A
hgnc_id
HGNC:3616
binding_type
receptor ligand recognition
cytotoxicity
NO
cytotoxicity_type
INDIRECT
cytotoxicity_mechanism
Tafasitamab binds CD19 on B cells; its Fc engages CD32A (FcγRIIA) on effector cells to trigger ADCC/ADCP, leading to killing of CD19+ B cells. CD32A-expressing cells serve as effectors, not targets, and are not directly killed.
enzyme_product
Off
epitope
Off
variant
Off
isoform
Off
hla_specific
Off
gated
Off
other_modifier
Fc region engagement on myeloid cells mediating ADCP
trial_id_tar_ref
drug_id_tar_ref
disease_id_tar_ref
nct_id_tar_ref
NCT05615636
disease_id_num_tar_ref
5739
drug_id_num_tar_ref
15598